

Aus dem Fachbereich Medizin
der Johann Wolfgang Goethe-Universität
Frankfurt am Main

Zentrum der Inneren Medizin
Medizinische Klinik I
Direktor: Prof. Dr. med. Stefan Zeuzem

**T-lymphozytäre und glykämische Marker bei
Typ 1 Diabetes mellitus nach drei Monaten hochdosierter
Vitamin D Therapie: eine randomisierte, placebo-kontrollierte Studie
mit cross-over Design (ViDDA1)**

Dissertation
zur Erlangung des Doktorgrades der Medizin
des Fachbereichs Medizin
der Johann Wolfgang Goethe-Universität
Frankfurt am Main

vorgelegt von
Dimitra Bogdanou
aus Thessaloniki

Frankfurt am Main, 15.04.2015

List of Contents

1. Introduction	1
1.1 Evolutionary perspective and historical aspects of vitamin D	2
1.1.1 Evolutionary perspective	2
1.1.2 Human history	3
1.2 Sources and metabolism of vitamin D	5
1.2.1 Vitamin D sources	5
1.2.2 Classification of vitamin D status	5
1.2.3 Overview of metabolism of vitamin D	6
1.2.4 Vitamin D storage	10
1.2.5 Factors that alter the cutaneous production of vitamin D	10
1.3 Receptors and biological functions of vitamin D	11
1.3.1 Vitamin D receptors	11
1.3.2 Classical vitamin D effects on calcium and phosphorus metabolism	15
1.3.3 Non-classical vitamin D effects	16
1.3.4 Vitamin D, acquired immunity and infectious diseases	17

1.3.5.	Vitamin D, insulin production, insulin resistance and metabolic syndrome	19
1.3.5.1	Vitamin D and b-cell function	19
1.3.5.2	Vitamin D, Body Mass Index and insulin sensitivity	21
1.3.5.3	Vitamin D as therapeutic agent in T2D	22
1.4	Vitamin D and T1D	23
1.5	Vitamin D and Autoimmunity	26
1.6	Working Hypothesis and study plan	27
2	Materials and Methods	29
2.1	Recruitment	29
2.2	Study design	29
2.2.1	Baseline visit (V0/V1) [month 0 = week 0]	31
2.2.2	Visits during the study (V2-V5)	32
2.3	Inclusion and exclusion criteria	32
2.4	Randomization and intervention	33
2.5	Main outcome variables	33
2.6	Blood sampling and laboratory assays	34
2.6.1	Quantification of vitamin D levels	34
2.6.2	DNA isolation for genotypic analysis	35
2.6.3	Quantification of human T lymphocytes	35
2.6.4	Genes, polymorphisms and genotyping	35
2.6.5	Clinical chemistry	36
2.7	Anthropometric characteristics and medical history	36

3	Registration and ethics	38
	3.1 Consort 2010 Checklist	39
4	Statistical analysis	41
	4.1 Effect sizes	42
	4.2 Carry-over effects	42
5	Results	43
	5.1 Participants	43
	5.2 Baseline characteristics	45
	5.2.1 High prevalence of vitamin D deficiency	45
	5.3 Endpoint variables	48
	5.3.1 Cellular parameters	48
	5.3.1.1 Tregs remained unchanged under vitamin D treatment	48
	5.3.1.2 % Monocytes and %activated monocytes showed a significant reduction under vitamin D treatment regardless of the regime sequence	48
	5.3.1.3 Baseline 1.25(OH) ₂ D ₃ status exercised no significant influence on the studied cellular markers	49
	5.3.2 Serum 25(OH)D ₃ and 1.25(OH) ₂ D ₃ levels	49
	5.3.2.1 Serum 25(OH)D ₃ and 1.25(OH) ₂ D ₃ increased significantly	49
	5.3.2.2 Insufficiency of 25(OH)D ₃ at baseline was associated with a stronger	

25(OH)D ₃ increase after treatment	49
5.3.2.3 Lower 1.25(OH) ₂ D ₃ levels at baseline	
were associated with a stronger	
1.25(OH) ₂ D ₃ Delta in the verum phase	50
5.3.3 Metabolic parameters of glucose utilization	51
5.3.3.1 Glycemic control was significantly	
improved under vitamin D treatment and	
total insulin demand declined	51
5.4 Clinical chemistry	51
5.5 Correlations between cellular and metabolic markers	52
5.6 Genes, polymorphisms and genotyping	52
5.7 Sub-group analysis	54
5.7.1 Gender	54
5.7.2 Genotyping analysis	55
5.7.2.1 SNPs and Th cells	55
5.7.2.2 SNPs and Tregs	57
5.7.2.3 SNPs and monocytes	61
5.7.2.4 SNPs and 25(OH)D ₃ - 1.25(OH) ₂ D ₃	
levels	62
5.7.2.5 SNPs and metabolic parameters	64
5.7.2.6 SNPs and clinical chemistry	66
5.7.3 Disease duration	66
5.7.4 BMI	66
5.7.5 25(OH)D ₃ status at baseline	67
5.7.5.1 Baseline 25(OH)D ₃ status had no influence	

	on cellular or metabolic effects of	
	vitamin D	67
	5.7.5.2 25(OH)D ₃ deficiency at baseline was	
	associated with a significant stronger	
	1.25(OH) ₂ D ₃ elevation under vitamin D	
	treatment	67
	5.7.5.3 Baseline 25(OH)D ₃ levels over the median	
	value demonstrated partially inverse	
	1.25(OH) ₂ D ₃ responses under treatment	68
	5.7.6 1.25(OH) ₂ D ₃ response under vitamin D treatment	69
	5.7.7 Tregs' response under vitamin D treatment	70
	5.7.8 Seasonal variations	70
6	Discussion	73
7	Summary	81
8	Zusammenfassung (summary in German)	83
9	Literature	85
10	Abbreviations	99
11	Figures and Tables	100
12	Acknowledgements	103
13	Curriculum vitae	104
14	Schriftliche Erklärung (written declaration in German)	109